482 related articles for article (PubMed ID: 25556904)
1. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
[TBL] [Abstract][Full Text] [Related]
3. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
Tieu J; Smith RM; Gopaluni S; Kumararatne DS; McClure M; Manson A; Houghton S; Jayne DRW
Front Immunol; 2021; 12():671503. PubMed ID: 34054846
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases.
Khojah AM; Miller ML; Klein-Gitelman MS; Curran ML; Hans V; Pachman LM; Fuleihan RL
Pediatr Rheumatol Online J; 2019 Aug; 17(1):61. PubMed ID: 31462263
[TBL] [Abstract][Full Text] [Related]
5. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.
Marco H; Smith RM; Jones RB; Guerry MJ; Catapano F; Burns S; Chaudhry AN; Smith KG; Jayne DR
BMC Musculoskelet Disord; 2014 May; 15():178. PubMed ID: 24884562
[TBL] [Abstract][Full Text] [Related]
6. Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients.
Labrosse R; Barmettler S; Derfalvi B; Blincoe A; Cros G; Lacombe-Barrios J; Barsalou J; Yang N; Alrumayyan N; Sinclair J; Ong MS; Camargo CA; Walter J; Haddad E
J Allergy Clin Immunol; 2021 Aug; 148(2):523-532.e8. PubMed ID: 33862010
[TBL] [Abstract][Full Text] [Related]
7. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study.
Podestà MA; Mescia F; Ricchiuto A; Smith R; Tedesco M; Cassia MA; Holle J; Sinico RA; Bruchfeld A; Gunnarsson I; Ohlsson S; Baslund B; Hruskova Z; Tesar V; Sabiu G; Gallieni M; Cid MC; Vaglio A; Harper L; Cozzolino M; Scolari F; Jayne D; Alberici F
Rheumatology (Oxford); 2023 Aug; 62(8):2850-2854. PubMed ID: 36562566
[TBL] [Abstract][Full Text] [Related]
8. Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.
Besada E
BMC Musculoskelet Disord; 2016 Jan; 17():6. PubMed ID: 26738559
[TBL] [Abstract][Full Text] [Related]
9. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia.
Kridin K; Ahmed AR
Autoimmun Rev; 2020 Mar; 19(3):102466. PubMed ID: 31917267
[TBL] [Abstract][Full Text] [Related]
10. Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases.
Boumaza X; Lafaurie M; Treiner E; Walter O; Pugnet G; Martin-Blondel G; Biotti D; Ciron J; Constantin A; Tauber M; Puisset F; Moulis G; Alric L; Renaudineau Y; Chauveau D; Sailler L
Int Immunopharmacol; 2023 Jul; 120():110342. PubMed ID: 37276827
[TBL] [Abstract][Full Text] [Related]
11. Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study.
Wade SD; Kyttaris VC
Rheumatol Int; 2021 Jun; 41(6):1115-1124. PubMed ID: 33811499
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab.
Filanovsky K; Miller EB; Sigler E; Berrebi A; Shvidel L
Recent Pat Anticancer Drug Discov; 2016; 11(2):228-35. PubMed ID: 26825174
[TBL] [Abstract][Full Text] [Related]
13. Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia.
Spadaro G; Pecoraro A; De Renzo A; Della Pepa R; Genovese A
Clin Immunol; 2016 May; 166-167():103-4. PubMed ID: 27063866
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia.
Caballero-Ávila M; Álvarez-Velasco R; Moga E; Rojas-Garcia R; Turon-Sans J; Querol L; Olivé M; Reyes-Leiva D; Illa I; Gallardo E; Cortés-Vicente E
Neuromuscul Disord; 2022 Aug; 32(8):664-671. PubMed ID: 35811274
[TBL] [Abstract][Full Text] [Related]
15. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.
Barmettler S; Ong MS; Farmer JR; Choi H; Walter J
JAMA Netw Open; 2018 Nov; 1(7):e184169. PubMed ID: 30646343
[TBL] [Abstract][Full Text] [Related]
16. Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections.
Langer-Gould A; Li BH; Smith JB; Xu S
Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200211. PubMed ID: 38507657
[TBL] [Abstract][Full Text] [Related]
17. Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD.
Mears V; Jakubecz C; Seeco C; Woodson S; Serra A; Abboud H
J Neuroimmunol; 2023 Apr; 377():578066. PubMed ID: 36917920
[TBL] [Abstract][Full Text] [Related]
18. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.
McAtee CL; Lubega J; Underbrink K; Curry K; Msaouel P; Barrow M; Muscal E; Lotze T; Srivaths P; Forbes LR; Allen C; Bernhardt MB
JAMA Netw Open; 2021 Feb; 4(2):e2036321. PubMed ID: 33533931
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.
Wijetilleka S; Mukhtyar C; Jayne D; Ala A; Bright P; Chinoy H; Harper L; Kazmi M; Kiani-Alikhan S; Li C; Misbah S; Oni L; Price-Kuehne F; Salama A; Workman S; Wrench D; Karim MY
Autoimmun Rev; 2019 May; 18(5):535-541. PubMed ID: 30844552
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome.
Inoki Y; Kamei K; Nishi K; Sato M; Ogura M; Ishiguro A
Pediatr Nephrol; 2022 May; 37(5):1057-1066. PubMed ID: 34606002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
